Download Image
    
Share
  
Post
Ibrutinib for COVID-19
1 study with 46 patients
Hospital Icon Control
Hospital Icon Ibrutinib Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Ibrutinib studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -9% Mortality -9% RCTs -9% Late -9% Favorsibrutinib Favorscontrol
Sep 20
2022
 Woyach et al., NCT04439006 Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
10 patient ibrutinib late treatment RCT with results not reported over 3 years after completion.
Mar 24
2022
 Coutre et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac104 Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
9% higher mortality (p=1), 9% lower hospital discharge (p=1), and 35% lower progression (p=0.7). RCT 46 hospitalized patients with severe COVID-19 showing no significant differences with ibrutinib treatment.